Clozapine associated with lower mortality than newer antipsychotics, study finds
This article was originally published in Scrip
Executive Summary
The second-generation antipsychotic clozapine (Novartis's Clozaril and generics) has unexpectedly been seen to be associated with a lower mortality rate than an older first generation antipsychotic, perphenazine, while other newer second-generation antipsychotics, such as AstraZeneca's Seroquel (quetiapine) and J&J's Risperdal (risperidone), have been shown to be associated with increased mortality, in a population-based study published in The Lancet online on July 13th.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.